ArticleClinical and experimental immunology1998
T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission.
Article in Clinical and experimental immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 80 citations in OpenAlex.
- The evolving landscape of vasculitis management: past, current and emerging.Rheumatology (Oxford, England) · 2025Review
- New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis.Frontiers in immunology · 2021Review
- Conformational changes in myeloperoxidase induced by ubiquitin and NETs containing free ISG15 from systemic lupus erythematosus patients promote a pro-inflammatory cytokine response in CD4Journal of translational medicine · 2020Article
- Cytokines: Names and Numbers You Should Care About.Clinical journal of the American Society of Nephrology : CJASN · 2015Review
- The immunopathology of ANCA-associated vasculitis.Seminars in immunopathology · 2014Review
- Analysis of T-cell receptor usage in myeloperoxidase--antineutrophil cytoplasmic antibody-associated renal vasculitis.Clinical and experimental nephrology · 2010Article
- ANCA patients have T cells responsive to complementary PR-3 antigen.Kidney international · 2008Article
- Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?Clinical and experimental immunology · 2008Article
- Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.Clinical and experimental immunology · 2005Review
- Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis.Clinical and experimental immunology · 2005Article
- Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology.Journal of clinical immunology · 2003Article
- Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis.Clinical and experimental immunology · 2003Article
- Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.Journal of clinical immunology · 2002Article
- Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis.Clinical and experimental immunology · 2001Article
- Cellular aspects of vasculitis--T cell-mediated aspects.Springer seminars in immunopathology · 2001Review
- In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG).Clinical and experimental immunology · 2000Article
- What you should know about PR3-ANCA. Evidence for the role of T cells in the pathogenesis of systemic vasculitis.Arthritis research · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ANCA with specificity for myeloperoxidase (MPO) and proteinase 3 (PR3) are present in patients with systemic vasculitis. The aim of this work was to determine whether such patients have T cell responses to these antigens and whether these responses are related to disease activity. Peripheral blood lymphocytes from 45 patients and 19 controls were cultured with ANCA antigens and proliferation measured. The antigens used were heat-inactivated (HI) MPO, HI PR3, native (non-HI) PR3, HI whole alpha-granules, and 25 overlapping peptides covering the entire PR3 sequence. Significant responses to both whole PR3 preparations were seen from patient and control groups, and to the alpha-granules from the patient group. Patients responded at all stages of disease: active, remitting, treated or untreated. Only two patients responded significantly to MPO. Responses were significantly higher with the patient group than the control group to all four whole ANCA antigens. Responses to those PR3 peptides containing epitopes known to be recognized by ANCA were detected from one patient. Thus, these studies demonstrate that T cells from vasculitis patients can proliferate to PR3 and occasionally to associated ANCA antigens. Further, responses may persist even after disease remission has been achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.